Literature DB >> 30784927

Knockdown of lncRNA HOXD-AS1 suppresses proliferation, migration and invasion and enhances cisplatin sensitivity of glioma cells by sponging miR-204.

Hui Zhou1, Yabin Ma1, Dequan Zhong1, Li Yang2.   

Abstract

Increasing evidence suggests the involvement of long noncoding RNAs (lncRNAs) in various biological process including cancer progression and drug resistance. LncRNA HOXD cluster antisense RNA 1 (HOXD-AS1) had been demonstrated to act as an oncogenic gene, contributing to the development and progression of several cancers. However, its functional role and molecular mechanism underlying glioma progression and cisplatin (DDP) resistance has not been well elucidated. In this study, we found that HOXD-AS1 was up-regulated in glioma tissues and cells and negatively correlated with survival time. HOXD-AS1 knockdown suppressed proliferation, migration and invasion as well as enhanced DDP sensitivity of glioma cells. Moreover, HOXD-AS1 could function as a miR-204 sponge in glioma cells. Overexpression of miR-204 could mimic the functional role of down-regulated HOXD-AS1 in glioma cells. Furthermore, miR-204 inhibition reversed the effect of HOXD-AS1 knockdown on cancer progression and DDP sensitivity of glioma cells. In conclusion, knockdown of HOXD-AS1 suppressed proliferation, migration and invasion and enhanced DDP sensitivity of glioma cells through sequestering miR-204, providing a promising therapeutic target for glioma patients.
Copyright © 2019 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Cisplatin; Glioma; HOXD-AS1; Migration and invasion; Proliferation; miR-204

Mesh:

Substances:

Year:  2019        PMID: 30784927     DOI: 10.1016/j.biopha.2019.108633

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  8 in total

1.  Promoter and enhancer RNAs regulate chromatin reorganization and activation of miR-10b/HOXD locus, and neoplastic transformation in glioma.

Authors:  Evgeny Deforzh; Erik J Uhlmann; Eashita Das; Aleksandra Galitsyna; Ramil Arora; Harini Saravanan; Rosalia Rabinovsky; Aditya D Wirawan; Nadiya M Teplyuk; Rachid El Fatimy; Sucika Perumalla; Anirudh Jairam; Zhiyun Wei; Leonid Mirny; Anna M Krichevsky
Journal:  Mol Cell       Date:  2022-04-06       Impact factor: 19.328

2.  Low GAS5 expression may predict poor survival and cisplatin resistance in cervical cancer.

Authors:  Xingyu Fang; Guanglei Zhong; Yuhan Wang; Zhongqiu Lin; Rongchun Lin; Tingting Yao
Journal:  Cell Death Dis       Date:  2020-07-13       Impact factor: 8.469

3.  HOXD-AS1 confers cisplatin resistance in gastric cancer through epigenetically silencing PDCD4 via recruiting EZH2.

Authors:  Yafei Ye; Shengnan Yang; Yanping Han; Jingjing Sun; Lijuan Xv; Lina Wu; Liang Ming
Journal:  Open Biol       Date:  2019-09-25       Impact factor: 6.411

4.  Long noncoding RNA DLEU1 aggravates glioma progression via the miR-421/MEF2D axis.

Authors:  Li Feng; Mingyuan He; Min Rao; Jiandong Diao; Yonggang Zhu
Journal:  Onco Targets Ther       Date:  2019-07-08       Impact factor: 4.147

5.  miR-363-3p induces EMT via the Wnt/β-catenin pathway in glioma cells by targeting CELF2.

Authors:  Bo Fan; Bolun Su; Guoqiang Song; Xin Liu; Zhongjie Yan; Shuai Wang; Fuguang Hu; Jiankai Yang
Journal:  J Cell Mol Med       Date:  2021-10-12       Impact factor: 5.310

Review 6.  Long non-coding RNAs regulation of therapeutic resistance.

Authors:  Susan Tsang; Tajhal Patel; Jason T Yustein
Journal:  Cancer Drug Resist       Date:  2019-09-19

Review 7.  NcRNAs: Multi‑angle participation in the regulation of glioma chemotherapy resistance (Review).

Authors:  Zhaomu Zeng; Yueyue Chen; Xiuchao Geng; Yuhao Zhang; Xichao Wen; Qingyu Yan; Tingting Wang; Chen Ling; Yan Xu; Junchao Duan; Kebin Zheng; Zhiwei Sun
Journal:  Int J Oncol       Date:  2022-05-04       Impact factor: 5.884

Review 8.  Role of Long Non-Coding RNAs in Conferring Resistance in Tumors of the Nervous System.

Authors:  Soudeh Ghafouri-Fard; Amin Agabalazadeh; Atefe Abak; Hamed Shoorei; Mohammad Mehdi Hassanzadeh Taheri; Mohammad Taheri; Guive Sharifi
Journal:  Front Oncol       Date:  2021-06-09       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.